SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

SANTA CRUZ BIOTECHNOLOGY, INC.

LGI1 (h2): 293T Lysate: sc-172088

SANTA CRUZ BIOTECHNOLOGY

The Power to Question

BACKGROUND

As human tumors progress to advanced stages, one genetic alteration that occurs at high frequency is a loss of heterozygosity (LOH) at chromosome 10. Mapping of homozygous deletions on this chromosome led to the isolation of the PTEN (also designated MMAC1 and TEP1), DMBT1 (for deleted in malignant brain tumors 1) and LGI1 (for leucine-rich gene-glioma inactivated 1) candidate tumor suppressor genes. The PTEN gene exhibits a high frequency of mutations in human glioblastomas and is also mutated in other cancers, including sporadic brain, breast, kidney and prostate cancers. Reduced levels of DMBT1 mRNA have been noted in gastrointestinal and esophageal cancers as well as in gliomas. LGI1, which is highly specific for neural tissues, shares homology with several transmembrane and extracellular proteins that function as receptors and adhesion proteins.

REFERENCES

1. Bigner, S.H., et al. 1988. Specific chromosomal abnormalities in malignant human gliomas. Cancer Res. 48: 405-411.
2. James, C.D., et al. 1988. Clonal genomic alterations in glioma malignancy stages. Cancer Res. 48: 5546-5551.
3. Steck, P.A., et al. 1997. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15: 356-362.
4. Li, J., et al. 1997. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
5. Somerville, R.P., et al. 1998. Molecular analysis of two putative tumour suppressor genes, PTEN and DMBT, which have been implicated in glioblastoma multiforme disease progression. Oncogene 17: 1755-1757.
6. Chernova, O.B., et al. 1998. A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors. Oncogene 17: 2873-2881.
7. Mori, M., et al. 1999. Lack of DMBT1 expression in oesophageal, gastric and colon cancers. Br. J. Cancer 79: 211-213.

CHROMOSOMAL LOCATION

Genetic locus: LGI1 (human) mapping to 10q23.33.

PRODUCT

LGI1 (h2): 293T Lysate represents a lysate of human LGI1 transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

APPLICATIONS

LGI1 (h2): 293T Lysate is suitable as a Western Blotting positive control for human reactive LGI1 antibodies. Recommended use: 10-20 µl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.